Inhibition of myeloperoxidase to treat left ventricular dysfunction in non-ischaemic cardiomyopathy

Simon Geissen^#^{1

2

3}, Simon Braumann^#^{1

2

3}, Joana Adler¹, Felix Sebastian Nettersheim^{1

3}, Dennis Mehrkens^{1

2

3}, Alexander Hof^{1

3}, Henning Guthoff^{1

3}, Philipp von Stein¹, Sven Witkowski⁴, Norbert Gerdes⁴, Frederik Tellkamp^{5

6}, Marcus Krüger^{5

6}, Lea Isermann^{2

5}, Aleksandra Trifunovic⁵, Alexander C Bunck⁷, Martin Mollenhauer^{1

2

3}, Holger Winkels^{1

2

3}, Matti Adam^{1

2

3}, Anna Klinke⁸, Gregor Buch⁹, Vincent Ten Cate⁹, Martin Hellmich¹⁰, Malte Kelm⁴, Volker Rudolph⁸, Philipp S Wild⁹, Stephan Rosenkranz^{1

2

3}, Stephan Baldus^{1

2

3}

Affiliations

¹ Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany.
² Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany.
³ Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany.
⁴ Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
⁵ Cologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases (CECAD) and Institute for Mitochondrial Diseases and Ageing, Medical Faculty, University of Cologne, Cologne, Germany.
⁶ University of Cologne, Department of Biology, Institute for Genetics, Cologne, Germany.
⁷ Department of Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
⁸ Agnes Wittenborg Institute for Translational Cardiovascular Research, Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, University Hospital of the Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
⁹ Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
¹⁰ Institute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

^# Contributed equally.

PMID: 39212229
DOI: 10.1002/ejhf.3435

Free article

Inhibition of myeloperoxidase to treat left ventricular dysfunction in non-ischaemic cardiomyopathy

Simon Geissen et al. Eur J Heart Fail. 2024 Oct.

Free article

. 2024 Oct;26(10):2269-2281.

doi: 10.1002/ejhf.3435. Epub 2024 Aug 30.

Authors

Affiliations

¹ Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany.
² Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany.
³ Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany.
⁴ Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
⁵ Cologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases (CECAD) and Institute for Mitochondrial Diseases and Ageing, Medical Faculty, University of Cologne, Cologne, Germany.
⁶ University of Cologne, Department of Biology, Institute for Genetics, Cologne, Germany.
⁷ Department of Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
⁸ Agnes Wittenborg Institute for Translational Cardiovascular Research, Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, University Hospital of the Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
⁹ Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
¹⁰ Institute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

^# Contributed equally.

PMID: 39212229
DOI: 10.1002/ejhf.3435

Abstract

Aims: Non-ischaemic cardiomyopathy (NICMP), an incurable disease terminating in systolic heart failure (heart failure with reduced ejection fraction [HFrEF]), causes immune activation, however anti-inflammatory treatment strategies so far have failed to alter the course of this disease. Myeloperoxidase (MPO), the principal enzyme in neutrophils, has cytotoxic, pro-fibrotic and nitric oxide oxidizing effects. Whether MPO inhibition ameliorates the phenotype in NICMP remains elusive.

Methods and results: Prognostic information from MPO was derived from proteomic data of a large human cardiovascular health cohort (n = 3289). In a murine model of NICMP, we studied the mechanisms of MPO in this disease. In a case series, the MPO inhibitor was also evaluated in NICMP patients. Individuals with increased MPO revealed higher long-term mortality and worsening of heart failure, with impaired prognosis when MPO increased during follow-up. MPO infusion attenuated left ventricular ejection fraction (LVEF) in mice with NICMP, whereas genetic ablation or inhibition of MPO decreased systemic vascular resistance (SVR, 9.4 ± 0.7 mmHg*min/ml in NICMP vs. 6.7 ± 0.8 mmHg*min/ml in NICMP/Mpo^-/-mice, n = 8, p = 0.006, data expressed as mean ± standard error of the mean) and improved left ventricular function (LVEF 30.3 ± 2.2% in NICMP vs. 40.7 ± 1.1% in NICMP/Mpo^-/- mice, n = 16, p < 0.0001). Four patients diagnosed with NICMP and treated with an MPO inhibitor over 12 weeks showed increase in LVEF, decline in natriuretic peptides and improved 6-min walking distance. MPO inhibitor-related changes in the proteome of NICMP patients predicted reduced mortality when related to the changes in the proteome of the above referenced cardiovascular health cohort.

Conclusions: Myeloperoxidase predicts long-term outcome in HFrEF and its inhibition elicits systemic anti-inflammatory and vasodilating effects which translate into improved left ventricular function. MPO inhibition deserves further evaluation as a novel, complementary treatment strategy for HFrEF.

Keywords: Endothelial dysfunction; HFrEF; Heart failure; Myeloperoxidase; Non‐ischaemic cardiomyopathy; Prognosis.

PubMed Disclaimer

References

1. Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi‐ethnic cohort study. Eur Heart J 2018;39:1770–1780. https://doi.org/10.1093/eurheartj/ehy005
1. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 2012;60:1455–1469. https://doi.org/10.1016/j.jacc.2011.11.082
1. Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in heart failure: JACC state‐of‐the‐art review. J Am Coll Cardiol 2020;75:1324–1340. https://doi.org/10.1016/j.jacc.2020.01.014
1. Ali M, Pulli B, Courties G, Tricot B, Sebas M, Iwamoto Y, et al. Myeloperoxidase inhibition improves ventricular function and remodeling after experimental myocardial infarction. JACC Basic Transl Sci 2016;1:633–643. https://doi.org/10.1016/j.jacbts.2016.09.004
1. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003;197:615–624. https://doi.org/10.1084/jem.20021426

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Inhibition of myeloperoxidase to treat left ventricular dysfunction in non-ischaemic cardiomyopathy

Affiliations

Inhibition of myeloperoxidase to treat left ventricular dysfunction in non-ischaemic cardiomyopathy

Authors

Affiliations

Abstract

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous